Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Randomized, Double-blind (Sponsor-open), Placebo-controlled, Parallel Group Study To Assess The Safety, Tolerability, Pharmacodynamics And Pharmacokinetics Of Multiple Oral Doses Of Pf- 06865571 For 2 Weeks In Adults With Nonalcoholic Fatty Liver Disease

Trial Profile

A Phase 1b, Randomized, Double-blind (Sponsor-open), Placebo-controlled, Parallel Group Study To Assess The Safety, Tolerability, Pharmacodynamics And Pharmacokinetics Of Multiple Oral Doses Of Pf- 06865571 For 2 Weeks In Adults With Nonalcoholic Fatty Liver Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs PF 06865571 (Primary)
  • Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Dec 2018 Status changed from suspended to recruiting.
    • 05 Nov 2018 Status changed from recruiting to suspended as sponsor elected to voluntarily pause study.
    • 21 Jun 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top